The Lupus Foundation of America has been talking with key stakeholders and companies involved in the drug supply chain, including state boards of pharmacy, federal government and agencies, and other important stakeholders - and our voices are clearly being heard.
The Food and Drug Administration issued an emergency authorization for the use of an anti-malaria drugs for the treatment of COVID-19, after the drug showed some potential as a treatment for the disease caused by the novel coronavirus, Politico reported.
"Currently, there is no proven way to prevent COVID-19 after being exposed", said Anna Bershteyn, assistant professor of population health at NYU and co-principal investigator on the study.
President Donald Trump had hinted of the use of the drugs, including chloroquine and hydroxychloroquine, as potential COVID-19 treatments.
"Anecdotal reports suggest that these drugs may offer some benefit in the treatment of hospitalized COVID-19 patients", said the statement. When the Secretary of Health and Human Services declares that issuance of an EUA is appropriate, the FDA has the regulatory emergency use authority to facilitate access to unapproved medical countermeasures or unapproved uses of approved medical countermeasures needed to prepare for and respond to chemical, biological, radiological and nuclear threats. For some COVID-19 patients, it can take up to 28 days to recover, if at all they did.
The drugs now are used to prevent or treat malaria infection, as well as to treat rheumatoid arthritis and lupus.
If the drug does not work, she said investigators can put their time and energy into other prevention and treatment interventions.
Doctors in France will now be able to treat COVID-19 patients after Didier Raoult, a renowned physician who specializes in infectious diseases, announced a new clinical trial's results.
The FDA's authorization does not mean hydroxychloroquine and chloroquine are specifically approved as safe and effective for use for COVID-19, but instead that they are available for use for COVID-19.